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A B S T R A C T
Recombinant-methionyl human glial cell line-derived neurotrophic factor (GDNF) is known for its
neurorestorative and neuroprotective effects in rodent and primate models of Parkinson’s disease
(PD). When administered locally into the putamen of Parkinsonian subjects, early clinical studies
showed its potential promise as a disease-modifying agent. However, the development of GDNF for
the treatment of PD has been signiﬁcantly clouded by ﬁndings of cerebellar toxicity after continuous
intraputamenal [1_TD$DIFF] high-dose administration in a 6-month treatment/3-month recovery toxicology
study in rhesus monkeys. Speciﬁcally, multifocal cerebellar Purkinje cell loss affecting 1–21% of the
cerebellar cortex was observed in 4 of 15 (26.7%; 95% conﬁdence interval [CI]: 10.5–52.4%) animals
treated at the highest dose level tested (3000 mg/month). No cerebellar toxicity was observed at
lower doses (450 and 900 mg/month) in the same study, or at similar or higher doses (up to
10,000 mg/month) in [14_TD$DIFF]subchronic or chronic toxicology studies testing intermittent intracerebro-
ventricular administration. While seemingly associated with the use of GDNF, the pathogenesis of
the cerebellar lesions has not been fully understood to date. This review integrates available
information to evaluate potential pathogenic mechanisms and provide a consolidated assessment of
the ﬁndings. While other explanations are considered, the existing evidence is most consistent with
the hypothesis that leakage of GDNF into cerebrospinal ﬂuid during chronic infusions into the
putamen down-regulates GDNF receptors on Purkinje cells, and that subsequent acute withdrawal of
GDNF generates the observed lesions. The implications of these ﬁndings for clinical studies with
GDNF are discussed.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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1.1. GDNF biology
Glial cell line-derived neurotrophic factor (GDNF), originally
isolated from a rat glioma cell line in the early 1990s (Lin et al.,
1993), is a distant member of the transforming growth factor-b
superfamily and a founding member of the GDNF family of ligands
(GFL), which includes neurturin, artemin and persephin (Air-
aksinen and Saarma, 2002). GDNF is a potent trophic factor for
midbrain dopaminergic neurons, central noradrenergic neurons,
spinal motor neurons and a variety of peripheral neurons. Outside
the nervous system, it acts as a morphogen in kidney development
and regulates spermatogonial differentiation (Airaksinen and
Saarma, 2002).
Following intracellular processing, GDNF is secreted as a
glycosylated mature protein of 134 amino acids (Lin et al.,
1993). The active compound is a disulﬁde-bonded homodimer of
approximately 30.4 kDa. As it lacks a speciﬁc carrier protein or
transporter at endothelial cells, GDNF does not cross the blood–
brain barrier (Kastin et al., 2003). In the adult human brain, GDNF is
expressed at very low levels, with the highest concentrations in the
caudate nucleus, putamen and substantia nigra (43–70 pg/mg
protein), signiﬁcantly lower concentrations in the cerebellum and
frontal cortex (10–15 pg/mg protein), and undetectable concen-
trations (<8 pg/mL) in cerebrospinal ﬂuid (CSF) (Mogi et al., 2001).
Cellular responses to all GDNF family ligands are mediated by a
multicomponent receptor complex consisting of the membrane-
anchoredGDNF family ligand receptor (GFR)a and transmembrane
RET receptor tyrosine kinase (Airaksinen and Saarma, 2002). Four
different GFRa proteins (GFRa-1–4) with unique binding afﬁnities
for each ligand have been identiﬁed. GDNF preferentially binds to
GFRa-1, but also interacts with GFRa-2 and GFRa-3, although at
lower afﬁnities (Airaksinen and Saarma, 2002). Effective GDNF
signaling via GFRa-1-RET additionally requires the presence of
heparan sulfate glycosaminoglycans which serve as high abun-
dance, low-afﬁnity receptors on the cell surface and in the
extracellular matrix (Barnett et al., 2002; Tanaka et al., 2002). In
cells lacking RET, especially in the forebrain, cortex and inner ear,
the neural cell adhesionmolecule (NCAM) has been identiﬁed as an
alternate signaling receptor for GDNF, again requiring the co-
expression of GFRa-1 for high afﬁnity binding (Paratcha et al.,
2003; Sariola and Saarma, 2003).
1.2. GDNF as a disease-modifying agent
Since its discovery, GDNF has received considerable attention as
a drug candidate for the treatment of a variety of neurological
diseases, most prominently Parkinson’s disease (PD), with the
understanding that the molecule needs to be delivered directly to
the tissue of interest so as to bypass the blood–brain barrier to
achieve meaningful tissue levels (Allen et al., 2013). In toxin-
induced rodent and nonhuman primate models of PD, GDNF has
been reproducibly shown to have both neurorestorative and
neuroprotective effects and to improve motor function when
delivered into the cerebral ventricles or directly into the
dopamine-deﬁcient striatum or substantia nigra (Tomac et al.,
1995; Gash et al., 1996; Bjorklund et al., 1997; Zhang et al., 1997;
Grondin et al., 2002).Based on these promising animal data, GDNF was tested in four
clinical studies enrolling a total of 99 subjects with PD. In the ﬁrst
study, monthly intracerebroventricular (ICV) bolus injections of
GDNF failed to provide clinical beneﬁt relative to placebo andwere
associated with a number of gastrointestinal side effects including
nausea, anorexia and vomiting and induced both weight loss and
hyponatremia in over half of the subjects (Nutt et al., 2003). A
postmortem analysis in one of the GDNF-treated study subjects
showed no GDNF immunoreactivity and no appreciable increase in
putamenal tyrosine hydroxylase immunoreactivity relative to age-
matched control cases with PD (Kordower et al., 1999). Therefore,
ICV delivery was subsequently replaced with intraputamenal (IPu)
delivery using implantable pumps. In addition, intermittent bolus
administration was replaced with continuous administration by
infusion, as the pumps required minimum basal infusion rates to
maintain proper function (Gash et al., 2005).
With these changes, GDNF showed strong signs of efﬁcacy in
two uncontrolled open-label Phase I studies (Gill et al., 2003;
Slevin et al., 2005), but was not signiﬁcantly different from placebo
in a randomized placebo-controlled Phase II study (Lang et al.,
2006). In contrast to the ICV study, GDNF was found to be well
tolerated and clinically safe in all of the IPu studies (Gill et al., 2003;
Slevin et al., 2005; Lang et al., 2006), althoughmore than half of the
subjects treated with GDNF developed clinically asymptomatic
immune responses with binding antibodies to the protein,
including 5 subjects with neutralizing antibodies (Tatarewicz
et al., 2007).
1.3. GDNF pharmacokinetics
Both in mammalian cell cultures and in vivo, GDNF undergoes
N-terminal proteolytic cleavage of 31–37 amino acid-long frag-
ments including the main heparin-binding site of the molecule
([15_TD$DIFF]Lau, [16_TD$DIFF] 996). Truncated GDNF remains biologically active in soluble
form, although not in immobilized matrix-bound form which
requires interactionwith the heparan sulfate chains of syndecan-3,
a transmembrane proteoglycan receptor, for proper signal
transduction (Bespalov et al., 2011).
Plasma concentrations in normal rhesus monkeys after single
ICV infusions of exogenous GDNF (recombinant-methionyl human
GDNF, r-metHuGDNF) at different doses (100 and 500mg) were
detectable only sporadically within the ﬁrst hour post dosing, the
highest individual value being 2.11 ng/mL (Lau, 1996). By contrast,
mean peak GDNF concentrations in CSF (CCSF) were 3554 ng/mL
(100mg dose) and 33,975 ng/mL (500mg dose), respectively (Lau,
1996). The terminal half-life in CSF of GDNF after these doses was
found to be assay-dependent. With an assay detecting only full-
length GDNF, the terminal half-life was 34 h, while it was almost
threefold longer (92 h) with an assay capturing both full-length
and truncated GDNF, indicating that in vivo processing of GDNF
occurs in CSF (Lau, 1996). The pharmacokinetics of GDNF in CSF of
normal rhesus monkeys were further found to hinge on the
proximity of the sampling site (lumbar spine or cisterna magna) to
the site of administration (intrathecal[17_TD$DIFF] lumbar or ICV). After
administration of the same single doses, higher peak concentra-
tions, larger areas under the curve and longer half-liveswere found
at the sampling site that was closer to the site of administration
than at the more distant sampling site (Wong, 2003a,b). Binding of
GDNF to local heparan sulfate glycosaminoglycans is considered
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2002; Tanaka et al., 2002).
Single infusions of 3 or 15mg of GDNF (infusion volume, Vi:
10 mL; concentration in the infusate, Ci: 0.3 or 1.5mg/mL) in
normal rat striatum resulted in substantially increased striatal
tissue concentrations of GDNF (Hadaczek et al., 2010). Basal
concentrations of endogenous GDNF in striatum were reported as
0.04–0.05 ng/mg protein in this study. Three days post infusion,
GDNF concentrations were 13.0 ng/mg protein at the low-dose
level and 59.8 ng/mg protein at the high-dose level. At both dose
levels, GDNF tissue concentrations rapidly decreased after Day 3,
but remained elevated as compared to baseline over periods of 2
(low-dose level) to 4 (high-dose level) weeks (Hadaczek et al.,
2010).
More recently, a study of the tissue clearance of GDNF following
single doses of 0.5, 1, 3 or 5 mg (Vi: [18_TD$DIFF]5mL; Ci: 0.1, 0.2, 0.6 or 1.0 mg/
mL) into the striatum of normal rats reported results that were
consistent with the ﬁndings of the above study and conﬁrmed the
extended dose-dependent pharmacokinetics of exogenous GDNF
in striatum (Taylor et al., 2013). At the 1.0 mg/mL level, GDNF tissue
concentrations were signiﬁcantly increased both 2 and 4 weeks
post infusion; at the 0.6 mg/mL level, they were signiﬁcantly
increased only 2 weeks post infusion; and at the 0.1 and 0.2 mg/mL
levels, no discernible changes in GDNF tissue concentrations were
observed (Taylor et al., 2013).
1.4. GDNF CNS-related toxicology program
Consistent with the need to deliver GDNF directly to the tissue
of interest so as to bypass the blood–brain barrier, the GDNF
toxicology program undertaken to support the clinical develop-
ment of GDNF had a special focus on studies testing ICV, IT and IPu
administration, using the rhesus monkey (Macaca mulatta) as the
standardmodel. Altogether, 11 studies involving 205 animals were
performed, including 6 ICV studies (N = 86), 1 IT study (N = 17) and
4 IPu studies (N = 102). None of the ICV/IT studies and only one of
the IPu studies have been published previously (Hovland et al.,
2007). Of particular importance, the program included 4 studies
testing the effects of long-term drug administration over 3–6
months in a total of 140 animals. Three of these studies employed
intermittent dosing ICV/IT protocols at biweekly or monthly
intervals (Orr, [19_TD$DIFF] 996; Orr, 1997 [20_TD$DIFF]b; Crosby Tompkins, 1998 [2_TD$DIFF]), while
the fourth one employed a continuous dosing IPu protocol (Boyd,
2006; Hovland et al., 2007). Dosing details for these subchronic and
chronic studies are presented in Table 1. In order to make the
studies comparable across the different dosing regimens, dose
levels are temporally normalized and detailed on the basis of GDNF
cumulative monthly doses.
Animals in the ICV/IT studies were dosed through a subcutane-
ous access port connected to a catheter which was implanted in a
lateral ventricle or the lumbar spine, respectively. Dosing consisted
of intermittent bolus infusions, and maximum GDNF dose levels
tested with ICV/IT were 10 mg given biweekly for 1 month (ICV)Table 1
Toxicology studies testing long-term delivery of GDNF to targets within the blood–brain
et al., 2007).
Route Tx/Ry [months] N Dosing scheme
Intermittent dosing into cerebrospinal ﬂuid compartment
IT 3/0 17 Monthly bolus admin
ICV 3/1 24 Biweekly bolus admi
ICV 6/3 27 Monthly bolus admin
Continuous dosing into putamenal parenchyma
IPu 6/3 72 Continuous, unilatera
N: number of animals in study; Tx/Ry: duration of treatment/recovery period; IT: intra(Orr, 1997a) ormonthly for 3months (IT) (Crosby Tompkins, 1998[2_TD$DIFF])
and 3 mg given biweekly for 3months (ICV) (Orr, 1996 [2_TD$DIFF]) ormonthly
for 6 months (ICV) (Orr, 1997 [20_TD$DIFF]b).
No mortality occurred during these studies. Acute clinical signs
observed on the treatment days included retching, vomiting,
salivation, lethargy and tremor; incidence and onset were dose-
related. These reactions were more severe with biweekly dosing
than with monthly dosing. Compared to control animals,
administration of GDNF was associated with reductions in mean
body weight, body weight gain and/or food and water consump-
tion. The magnitude of these effects was generally modest and
appeared to be dose-related, although weight differences relative
to control animals did not generally reach the level of statistical
signiﬁcance (Orr, [19_TD$DIFF] 996; Orr, 1997a,[20_TD$DIFF]b; Crosby Tompkins, 1998[2_TD$DIFF]).
Histopathological effects included two main types of ﬁndings,
(1) increased inﬂammatory changes in various regions including
meninges, ventricular system, spinal cord, spinal nerve roots,
perineural tissue and catheter tract; and (2) axonal sprouting with
Schwann cell hyperplasia in dorsal spinal nerve roots, sympathetic
nerves and/or pia mater. Both types of changes were dose-related
in all studies and appeared to be at least partially reversible after
one (inﬂammation) or three (Schwann cell changes) months of
recovery (Orr, [19_TD$DIFF] 996; Orr, 1997a,[20_TD$DIFF]b; Crosby Tompkins, 1998[2_TD$DIFF]). In the
3-month IT administration study, axonal degeneration in the
lumbosacral spinal regionwas seen as an additional ﬁnding at dose
levels of 1750mg [21_TD$DIFF]/month or more (Crosby Tompkins, 1998 [2_TD$DIFF]).
Although a GDNF-speciﬁc drug effect cannot be ruled out, it
seems more likely that the increased inﬂammatory changes (and
secondary axonal degeneration after IT administration) repre-
sented a nonspeciﬁc response to high local concentrations of a
heterologous protein resulting from the combination of high doses
and GDNF binding to local heparan sulfate glycosaminoglycans
(Barnett et al., 2002; Tanaka et al., 2002). In contrast, the Schwann
cell effects are probably attributable to the intrinsic pharmacologic
activity of GDNF (Hoke et al., 2003).
For the IPu studies, animals were implanted with a single
unilateral IPu catheter (1 mm outer diameter) that was connected
to a microinfusion pump implanted in the abdominal wall. The
pump reservoirs were reﬁlled with infusion solution on a monthly
basis, and dosing occurred via continuous infusion at infusion rates
of 6–24 mL/h (Boyd, 2005a,b; Boyd, 2006; Hovland et al., 2007).
In a subacute IPu study, 20 animals were treatedwith vehicle or
30, 100 or 500mg GDNF per day (Ci: 0.1, 0.33 or 1.67 mg/mL),
corresponding to 900, 3000 or 15,000 mg/month. All infusions
were delivered at a constant rate of 12.5 mL/h for [22_TD$DIFF]1 [23_TD$DIFF]month (Boyd,
2005b).
Treatment with GDNF was generally well tolerated, although
sustained body weight loss and reduced body weight gain relative
to control animals were observed at dose levels of 3000mg/month
or more. At the 15,000 mg/month dose, clinical laboratory
alterations including hyponatremia, hypochloremia, hyperkale-
mia, hypocholesteremia, changes in the plasma protein proﬁle and
aciduria were observed after 3 weeks of treatment or later. One ofbarrier in rhesus monkeys (Orr, [11_TD$DIFF] 996; Orr, 1997b; Crosby Tompkins, [12_TD$DIFF] 998; Hovland
Cumulative GDNF dose [mg/month]
istration 0 300 1750 10,000
nistration 0 600 2000 6000
istration 0 75 500 3000
l infusion 0 450 900 3000
thecal; ICV: intracerebroventricular; IPu: intraputamenal.
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because of a moribund condition associated with dehydration,
hypothermia, recumbency and clinical laboratory abnormalities
(Boyd, 2005b). Necropsy did not reveal any explanation for the
condition, and the ﬁndings could not be replicated in a repeat study
treating 3 additional animals at the same dose (Boyd, 2005a). No
drug-related gross lesions or organ weight changes were observed
at necropsy in any of the other animals, and no drug-related
microscopic changes were noted outside the CNS (Boyd, 2005b).
Within the CNS, both thickened meninges and Schwann cell
hyperplasia were observed in the 3000mg/month and 15,000 mg/
month groups and were considered to be related to the intrinsic
activity of GDNF. In addition, nonspeciﬁc perivascular leukocyte
inﬁltrates were observed along the catheter tract and/or at the
infusion site in all groups and increased in incidence and severity
as a function of dose. In the 15,000 mg/month group, 3 animals had
local edema, 2 of them together with focal necrosis and
degenerated neurons (Boyd, 2005b). These ﬁndings were reﬂected
in end-of-treatment magnetic resonance imaging (MRI) scans,
where a hyperintense diffuse T-2 weighted signal and T-2 and T-1
weighted ring lesions with localized gadolinium enhancement
were seen at the infusion sites in the 3000mg/month and
15,000 mg/month groups. The above ﬁndings were interpreted
as a standard nonspeciﬁc response to a foreign protein (Boyd,
2005b). Similar ﬁndings including signiﬁcant vacuolations at the
infusion site were previously made in rats 5 weeks after single
retronigral infusion with GDNF at a very high concentration (Ci:
25mg/mL; rate: 1.0 mL/min; Vi: 4mL) (Bowenkamp et al., 1995).
However, the same observations were made in control animals
receiving cytochrome C at the same concentration and infusion
protocol. This, together with the fact that the ﬁndings were
markedly reduced when the GDNF/cytochrome C concentrations
were halved while the infusion volumes were doubled to keep the
total protein dose constant, indicated that the effects were not
related to the intrinsic activity of GDNF, but to local accumulation
of protein (Bowenkamp et al., 1995).
On the basis of these ﬁndings, the no observed adverse effect
level (NOAEL) in this study was determined to be 900 mg/month
(Boyd, 2005b).
In a chronic IPu study, 72 animals were treated with vehicle or
15, 30 or 100mg GDNF per day (Ci: 0.1, 0.2 or 0.67mg/mL),
corresponding to 450, 900 or 3000mg/month (Hovland et al.,
2007). All infusions were given at a constant rate of 6.25mL/h for
6months (6/sex/group), followed by a 3-month recovery period (3/
sex/group) (Hovland et al., 2007).
Twelve unscheduled sacriﬁces and 1 death occurred over the
course of the study. The single mortality and 11 of the sacriﬁces
were secondary to pump-related complications. The remaining
sacriﬁce (900mg/month) was due to disseminated intravascular
coagulopathy, which was probably secondary to chronic exposure
to GDNF as a human antigen. No other possibly immune-mediated
events were observed, and clinical observations, including physi-
cal, electrocardiographic, neurological and ophthalmological
examinations, were unremarkable over the course of the study.
No toxicologically signiﬁcant hematology, serum chemistry,
coagulation, or urinalysis parameters were observed. Furthermore,
CSF total cell count and chemistry proﬁles were unremarkable
(Hovland et al., 2007).
Statistically signiﬁcant drug-related body weight loss and
marked reductions in body weight gain relative to control animals
were observed in the 3000mg/month group. Changes in food
consumption paralleled the bodyweight effects. A rebound in body
weight gain occurred during the recovery period. No relevant test
article-related gross observations or organ weight changes were
noted at the end of treatment or recovery necropsies (Hovland
et al., 2007).On-treatment MRI scans showed a circumferential increase in
the uptake of gadolinium contrast at the catheter tip in T-1
weighted sequences which was often superimposed with a diffuse
T-2 fast spin echo (FSE) hyperintense signal in all groups. However,
the frequency of the T-1 contrast ﬁndings increased over time in
the 3000mg/month group, while it remained relatively constant in
all other groups. At 6 months, the frequency was higher in the
3000mg/month group (66.7%) than in the 450mg/month (28.6%)
and 900 mg/month (26.7%) groups, with the control group having
the lowest frequency (13.3%). Similarly, the frequency of the
diffuse T-2 FSE hyperintense signal at 6 months was higher in the
3000mg/month group (93.3%) than in the 450mg/month (71.4%)
and 900 mg/month (73.3%) groups, and the control group again had
the lowest frequency (40.0%). Evaluating these ﬁndings in their
entirety, it was concluded that they were likely the result of
localized edema and disruption of the blood–brain barrier due to
inﬂammation following local protein accumulation (Hovland et al.,
2007).
GDNF immunohistochemistry demonstrated the presence of
GDNF at the infusion site around the catheter tip in a radially
diffuse pattern in all actively treated groups. In general, the
intensity of staining increased with increasing dose and tended to
be most pronounced in white matter tracts. In animals that
developed a cavity or pronounced inﬂammatory reaction at the
catheter site, the infused GDNF tended to be trapped within the
cavity or inﬂammatory zone. Staining was consistently present in
actively treated animals at the end of recovery, although less
pronounced than at the end of treatment (Hovland et al., 2007).
Meaningful microscopic observations in actively treated
animals were limited to the CNS and/or closely associated
structures. Speciﬁc changes including meningeal Schwann cell
hyperplasia and meningeal thickening due to axonal proliferation,
either underlying the medulla oblongata or overlying various
spinal cord segments, were observed in the 900mg/month (1/9)
and 3000mg/month (7/10) groups at the end of treatment and in
the 3000mg/month (3/5) group at the end of recovery. Notable
nonspeciﬁc microscopic lesions included slight-to-mild inﬂam-
mation at or adjacent to the catheter tract or infusion site. The
inﬁltrates differed only slightly between actively treated animals
and controls, in particular at 450mg/month and were not
considered clinically relevant up to 900 mg/month (Hovland
et al., 2007).
Very importantly, this study yielded unexpected signs of
cerebellar toxicity in 4 of 15 animals given 3000 mg/month
(Hovland et al., 2007). The potential mechanisms underlying this
ﬁnding are discussed in detail in the following sections.
On the basis of the aggregate ﬁndings from this study, including
the cerebellar lesions, the NOAEL was determined to be 900mg/
month (Hovland et al., 2007).
2. Cerebellar lesions
At the end of the 3-month recovery period,multifocal cerebellar
Purkinje cell loss affecting approximately 21% of the cerebellar
cortex was observed in one animal treated for 6 months at the
3000mg/month dose in the chronic IPu study (Hovland et al.,
2007). Triggered by this ﬁnding, a systematic review of all
prospectively prepared and additional for-cause cerebellar sec-
tions from the other animals in this study and of all available
cerebellar sections from the animals in the other subchronic and
chronic toxicity studies of the program (as presented in Table 1)
was performed. This analysis revealed similar, but less extensive
(1–3% of cerebellar cortex) lesions in three other animals given
3000mg/month in the chronic, continuous dosing IPu study. Two
of these animals belonged to the recovery cohort, the third one to
the main study cohort. In contrast, no lesions were found in any
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Fig. 2. Cerebellar astrocytosis in a high-dose (3000 mg/month) animal (Hovland
et al., 2007). 10 objective, anti-GFAP stain. Panel A: control animal with normal
Purkinje cells (arrows), densely populated granule cell layer (G) and uniform
molecular layer (M). The intensity of anti-GFAP staining in white matter (W) is
M. Luz et al. / NeuroToxicology 52 (2016) 46–5650animal treated with 450mg/month or 900mg/month in this study,
or in any animal treated in any of the other subchronic and chronic
toxicity studies. In summary, the occurrence of cerebellar Purkinje
cell loss was conﬁned to the 3000mg/month dose group in the
continuous dosing IPu study, where lesions were observed in 4 of
15 (26.7%; 95% conﬁdence interval [CI]: 10.5–52.4%) treated
animals (Hovland et al., 2007).
The severity of lesions in affected animals was generally
minimal to moderate, but varied considerably by focus and by
animal. Microscopic ﬁndings ranged from patchy Purkinje cell loss
with proliferation of Bergman’s glia, astrocytosis and vacuolation
in the molecular layer to more extensive lesions with translobar,
nearly full thickness loss of Purkinje cells. This was associatedwith
minimal to moderate atrophy of the molecular layer (suggesting
degeneration of Purkinje cell dendrites) and granule cell loss at
some foci (Fig. 1). The loss of granule cells was probably the result
of retrograde degeneration caused by the loss of their postsynaptic
targets, i.e. Purkinje cells (Sarna and Hawkes, 2003; Cendelin,
2014).
Increased glial ﬁbrillary acidic protein (GFAP) staining in
affected areas was indicative of proliferation or thickening of
astrocytic processes (Fig. 2).
None of the lesions were associated with increased Fluoro-Jade
B staining which would have been indicative of ongoing and
progressive neuronal degeneration. Also, there were no signs of
microgliosis, suggesting that the lesions were mature and inactive,
with no evidence of ongoing pathogenesis (Hovland et al., 2007).
Cumulatively, the lesions affected approximately 21% of the
cerebellar cortex in the animal that demonstrated the toxicity, and
1%, 3% and 3% in the other three affected animals. Mapping of the
lesions showed that they were distributed randomly throughout
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Fig. 1. Cerebellar Purkinje cell loss in a high-dose (3000 mg/month) animal
(Hovland et al., 2007). 40 objective, H&E stain. Panel A: control animal with
normal Purkinje cells (arrows), densely populated granule cell layer (G) and
uniform molecular layer (M). Panel B: high-dose (3000 mg/month) animal no. 71,
necropsied at the end of recovery, showing a hypocellular granule cell layer (G), an
absence of Purkinje cells, and a vacuolated and loosely arranged molecular layer
(M).
typical for the normal cerebellum. Panel B: high-dose (3000 mg/month) animal no.
71, necropsied at the end of recovery, showing increased anti-GFAP staining in the
molecular layer in areas where Purkinje cells are absent and an abrupt decrease in
anti-GFAP staining in areas where Purkinje cells are present (arrows).the cerebellar cortex among multiple folia in both hemispheres
and the vermis, with no predilection for any speciﬁc region
(Hovland et al., 2007).
While the study was not speciﬁcally designed to detect subtle
changes in motor function, there was no evidence of neurological
deﬁcit or motor dysfunction in affected animals at cage side
observations or neurological/physical examinations. Motor changes
that might have been expected include ataxia, in particular gait
ataxia, and tremor (Wolf et al., 1996; Tolbert et al., 2001; Sarna and
Hawkes, 2003). A strong association appears to exist between the
extent and type of spatial loss of Purkinje cells and the severity of
clinical signs (Wolf et al., 1996). Therefore, the most likely
explanation for the absence of motor changes in the study is the
limited extent and random distribution of the lesions across the
cerebellar cortex of the affected animals. This would also explain
why standard sequential [24_TD$DIFF]MRI[6_TD$DIFF] did not reveal any ﬁndings, and why
the brains of the affected animals were grossly unremarkable at
visual evaluation at necropsy (Hovland et al., 2007).
3. Potential pathogenic mechanisms
The observed cerebellar lesions were unexpected and as far as
can be determined, there are no other published reports that GDNF
produces Purkinje (or other neuronal) cell loss in any species.
Potential pathogenic mechanisms are considered below.
3.1. Excitotoxicity-mediated mechanisms
Purkinje cells are the largest neurons in the cerebellar cortex and
play a central role in motor coordination and motor learning. They
Table 2
Incidence of anti-GDNF antibodies in serum and cerebrospinal ﬂuid (Hovland et al.,
2007).
Dose group Serum antibodies CSF antibodies
Binding Neutralizing Binding Neutralizing
0mg/month 6% 0% 0% 0%
450mg/month 69% 38% 19% 19%
900mg/month 94% 50% 18% 18%
3000mg/month 100% 33% 6% 6%
All active dose groups 88% 40% 14% 14%
Incidence reﬂects positive responses at one or more time points.
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ponto-cerebellar pathway and via climbing ﬁbers from the olivo-
cerebellar pathway. A remarkable feature of Purkinje cell circuitry is
its territorial organization. Each Purkinje cell receives input at its
distal dendrites from 105[13_TD$DIFF] to 106 parallel ﬁbers, although only one or
two of these originate from the same granule cell. Thus, excitation of
a singleparallel ﬁber onlyweaklydepolarizes thePurkinje cell that it
innervates. By contrast, the same cell is powerfully and exclusively
innervated at its proximal dendrites via hundreds of synapses
formed by a single climbing ﬁber originating in the inferior olive
(Watanabe, 2008). Not surprisingly, the robust excitatory innerva-
tion of Purkinje cells makes them particularly vulnerable to
glutamate-mediated excitotoxicity (Sarna and Hawkes, 2003).
3.1.1. Ponto-cerebellar pathway
Although the putamen and cerebellum have no direct functional
connection, the cerebellum receives input from the putamen via the
direct and indirect motor pathways and further via the cortico-
ponto-cerebellar pathway. It is possible that GDNF-induced
sustained increase in putamenal dopamine activity would lead to
lasting overstimulation of the direct motor pathway coupled with
inhibition of the indirect pathway. This would involve increased
inhibitory output (through the direct pathway) and decreased
excitatory output (through the indirect pathway) to the internal
globus pallidus, both resulting in a disinhibition of thalamic motor
neurons. Conceivably, increased glutamatergic stimulation of the
neocortex resulting from this thalamic disinhibition could then lead
to sustained overstimulation of the cerebellar cortex and excito-
toxicity-mediated degenerative foci. This overstimulation would
occur via the cortico-ponto-cerebellar pathway involving the
cortico-pontine, mossy and parallel ﬁber systems.
There are, however, two important points that argue against the
hypothesis that the observed cerebellar lesions may have been
caused by an excitotoxic mechanism. First, the speciﬁc architec-
ture of the parallel ﬁber system inevitably leads to activation of
major Purkinje cell clusters because, as described above, depolari-
zation of a single Purkinje cell requires simultaneous excitatory
input from a large number of granule cells which in turn project to
and activate large numbers of adjacent Purkinje cells. Recruitment
of the requisite number of granule cells is enabled by extensive
branching of mossy ﬁbers in white matter which ensures that any
single mossy ﬁber axon simultaneously projects to a large number
of granule cells (Llina´s et al., 2003). Therefore, excitotoxic lesions
following activation of the cortico-ponto-cerebellar pathway
would be expected to show a replicable contiguous and homoge-
neous distribution pattern across individual lobules or the entire
cerebellar cortex rather than the spotted, heterogeneous distribu-
tion pattern observed in the affected animals.
Second, while continuous intrastriatal infusions produced
signiﬁcant increases in putamenal dopamine metabolites in
nonhuman primates, the corresponding increase in putamenal
dopamine concentrations was modest and insigniﬁcant (Maswood
et al., 2002; Grondin et al., 2002). More importantly, the increase
was regionally limited and not different from the increase induced
by continuous ICV infusions (Grondin et al., 2002). This, together
with the observation that the clinical effects of continuous dosing
intrastriatal and intermittent dosing ICV administration in 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned
monkeys were highly similar (Gash et al., 1996), leads to the
conclusion that cerebellar lesions, if induced as hypothesized
above, should also have been observed in at least somemonkeys in
the ICV toxicology studies; however, this was not the case.
3.1.2. Olivo-cerebellar pathway
The olivo-cerebellar pathway involves distinct three-element
loops between an individual olivary subnucleus, zonally organizedPurkinje cells and a central cerebellar nucleus. The olivary
subnucleus of any given loop projects contralaterally to one or
more longitudinal zones of Purkinje cells that in turn project to a
given cerebellar target nucleus. The same cerebellar nucleus also
receives collaterals from and reciprocally projects to the olivary
subnucleus of the loop (De Zeeuw et al., 1998). The anatomical unit
consisting of a particular Purkinje cell zone with its speciﬁc olivary
input and the innervation of the associated cerebellar nucleus has
been termed a cerebellar module (De Zeeuw et al., 1998).
The modular organization of the olivo-cerebellar circuitry
forms the anatomical basis of the neuropathological ﬁndings
observed after systemic administration of the indole alkaloids,
ibogaine and harmaline. Both agents induce sustained activation of
neurons in the inferior olive leading to selective excitatory injury
and degeneration of Purkinje cells in narrow parasagittal bands in
the cerebellar vermis (O’Hearn and Molliver, 1993; O’Hearn and
Molliver, 1997). The absence of any such pattern in the continuous
dosing IPu GDNF study makes it highly unlikely that the GDNF-
induced cerebellar lesions were due to excitotoxicity mediated via
the olivo-cerebellar pathway. On the contrary, exogenous GDNF
has been shown to delay hereditary Purkinje cell degeneration via
intact olivo-cerebellar projections (Hess et al., 2003).
3.2. Ischemia
Purkinje cells are particularly sensitive to ischemia and other
forms of energy depletion, presumably due to reduced resistance
to the intense synaptic input from the inferior olive upon
restoration of blood ﬂow (Welsh et al., 2002). Consistent with
this hypothesis, the patterned loss of Purkinje cells after global
brain ischemia resembles the ibogaine-induced striped pattern of
neurodegeneration. In addition, elimination of climbing ﬁber input
from the inferior olive has been shown to protect Purkinje cells
from early ischemic damage (Welsh et al., 2002). The absence of
any discernible pattern in the distribution of cerebellar lesions in
the continuous dosing IPu GDNF study essentially precludes an
ischemic event as the underlying mechanism. This is further
supported by the absence of neuropathology in other highly
ischemia-sensitive brain areas such as the striatum or the CA1 area
of the hippocampus.
3.3. GDNF immunogenicity
As expected of a recombinant human protein administered to
nonhuman primates, GDNF was highly immunogenic. As detailed
in Table 2, high incidences of binding (88%) and neutralizing (40%)
anti-GDNF antibodies were found in the serum of drug-treated
animals at least once during the study (Hovland et al., 2007).
The respective incidences in CSF were 14% for both types of
antibodies, and all animals with antibodies in CSF also tested
positive for antibodies in serum (Boyd, 2006; Hovland et al., 2007).
The incidence of binding antibodies in serum peaked early in the
study, on Day 2, when 81% of drug-treated animals tested positive,
Table 3
Mean GDNF levels (pg/mL) in cerebrospinal ﬂuid (Hovland et al., 2007).
Dose group On treatment Recovery
4 weeks 26 weeks 39 weeks
N Mean SD N Mean SD N Mean
450mg/month 15 297 393 14 20 51 4 BLQ
900mg/month 15 602 1260 14 566 771 6 BLQ
3000mg/month 15 12,200 40,000 14 5950 8270 5 BLQ
N: number of samples at sampling time; BLQ: below the limit of quantiﬁcation.
Table 4
Individual GDNF levels (pg/mL) in cerebrospinal ﬂuid of animals in the high dose
group (3000mg/month) (Hovland et al., 2007).
Animal ID On treatment End of recovery
4 weeks 26 weeks 39 weeks
Affected
28 2099 BLQ N/A
34 161,775 BLQ BLQ
71 2940 4409 BLQ
72 1710 BLQ BLQ
Unaffected
M. Luz et al. / NeuroToxicology 52 (2016) 46–5652while only 66% tested positive at Week 26 and 47% at the recovery
time point. The incidence of neutralizing antibodies in serum
gradually increased from Day 2 (21%) to Week 26 (34%), before it
went down again to 20% at the recovery time point (Boyd, 2006).
CSF samples also showed higher antibody incidences later in the
study (Week 26 vs.Week 4) butwere negative for both binding and
neutralizing antibodies at the recovery time point (Boyd, 2006;
Hovland et al., 2007). Only the incidence of binding antibodies in
serum appeared to be dose dependent, while no dose dependency
was observed for neutralizing antibodies in serumor for antibodies
of any type in CSF (Hovland et al., 2007).
Consistent with expectations based on the low number of B
cells in CSF (0.004  106 cells/L) (de Graaf et al., 2011), these
ﬁndings suggest that antibody formation occurred as a result of
systemic exposure. Consistent systemic exposure to GDNF was
encountered via the surgical implantation of the pump/catheter
system and the pump reﬁll and ﬂushing procedures that were
performed at 2-week intervals, starting at surgery, i.e. approxi-
mately 4 weeks prior to the initiation of study treatment (Hovland
et al., 2007).
Computer analysis of the human GDNF sequence revealed
two immunodominant major histocompatibility complex (MHC)
class II T cell epitopes within the C-terminal domain of the
molecule between amino acids 31–43 and 69–81 (Tatarewicz
et al., 2007). The effect of these intrinsic T cell epitopes may
have been exposed or potentially augmented in the recombinant
protein that is produced in Escherichia coli and lacks glycosyla-
tion at amino acids 49 and 85 of the endogenous molecule. This
supports the hypothesis that the presence of neutralizing
antibodies in serum and the appearance of antibodies in CSF
was caused by a T-cell-mediated maturing immune response
(Tatarewicz et al., 2007).
Importantly, a correlation of Purkinje cell loss and the presence
of anti-GDNF antibodies in serum or CSF could not be established
(Hovland et al., 2007). Speciﬁcally, no animalwith Purkinje cell loss
presented with pre-existing antibodies and although all four
affected animals, like all unaffected animals in the 3000mg/month
dose group, developed binding antibodies in serum during
treatmentwithGDNF, only two also tested positive for neutralizing
antibodies and none had antibodies in CSF.
There were signs of nonspeciﬁc inﬂammation locally along the
catheter tracts and at the infusion sites at the end of the treatment
period in all treatment groups. The changes were more consistent
and more pronounced in drug-treated animals, speciﬁcally in the
two high-dose groups (Hovland et al., 2007). The inﬂammatory
reaction was typically characterized by lymphocyte/eosinophil
inﬁltrates at the catheter tract or in the perivascular space adjacent
to the catheter tract (Hovland et al., 2007). By contrast, no such
inﬂammatory reactions and in particular, no parenchymal T cell
margination, was observed in areas of Purkinje cell loss (Hovland
et al., 2007).
3.4. Exposure to GDNF in cerebrospinal ﬂuid
Several interesting observations can be made with respect to
GDNF CCSF:29 2569 171 N/A
32 3578 5185 N/A
33 936 8607 N/A
1. G35 1048 15,968 BLQ
64 1355 2345 N/A
65 8887 30,968 N/A
66 1093 15,392 N/A
67 1203 2403 N/A
68 1630 NS N/A
69 562 BLQ N/A
70 1065 144 BLQ
BLQ: below the limit of quantiﬁcation. NS: no sample. N/A: not applicable.DNF CCSF was quantiﬁable in the vast majority of on-treatment
samples in all active groups, although individual values were
highly variable within any given dose group. This very likely
reﬂects signiﬁcant leakage of drug from the infusion site into the
CSF due to the use of large (1 mm outer diameter), non-step
design catheters, with the individual extent of leakage depend-
ing on factors such as the exact location of the catheter tip (Chen
et al., 1999; Morrison et al., 1999; Krauze et al., 2005; Fiandaca
et al., 2008; Allard et al., 2009; Yin et al., 2009a).2. As shown in Table 3, mean GDNF CCSF increased with dose at
both sampling times during treatment (Weeks 4 and 26).
Similarly, the frequency of quantiﬁable levels also increased
with dose, and all animals in the 3000mg/month group had
quantiﬁable levels after 4 weeks.3. Mean GDNF CCSF nominally decreased between Weeks 4 and
26 in all groups. An appreciable 93% decrease was seen in the
low-dose group, while the mid-dose group remained effectively
unchanged (6%), and the high-dose group showed a 51%
decrease. Assuming no change in the rate of GDNF transfer into
the CSF compartment, this pattern would be consistent with a
modest induction over time of the assumed GDNF processing in
CSF.4. No quantiﬁable GDNF CCSF values were found at the end of the
recovery period which is consistent with pharmacokinetic data
indicating that the terminal half-life of GDNF in CSF following
single dose ICV administration in rhesus monkeys is 34 h (Lau,
1996).
At ﬁrst glance, these observations could be taken to support the
hypothesis that exposure to high GDNF CCSF may have caused the
cerebellar lesions. However, a correlation between the presence of
Purkinje cell loss and peak GDNF CCSF values could not be
established at a group level. Speciﬁcally, although the animal with
the single highest GDNF CCSF value (no. 34: 161,775 pg/mL) was
among the affected animals, 8 of 11 unaffected animals had peak
values that were well within the range of the affected animals
(1710–161,775 pg/mL). The individual values of all animals in the
high-dose group are presented in Table 4.
Purkinje cells are known to express both GFRa-2 and c-RET
mRNA (Burazin and Gundlach, 1999). While GDNF preferentially
binds toGFRa-1, it also binds toGFRa-2, although at lower afﬁnities
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Fig. 3. Individual GDNF Levels (pg/mL) in cerebrospinal ﬂuid of animals in the high-
dose group (3000 mg/month) (Hovland et al., 2007). Animals grouped together on
the left side (no. 28, 34, 71, 72) had cerebellar lesions, animals grouped together on
the right side (no. 29, 32, 33, 35, 64–70) did not have lesions. Animals 34, 35, 70, 71,
72 were in the recovery group, all other animals were in the main group. Values
below the level of quantiﬁcation are represented as 2 pg/mL. The 26-week sample
of animal no. 68 is missing.
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Purkinje cells are responsive to GDNF in vitro, suggesting that
GDNF isapotent survival anddifferentiation factor for theseneurons
(Mount et al., 1995). Consistent with these ﬁndings, GDNF injected
into the cisterna magna improves cerebellar Purkinje neuron
function in aged F344 rats (Bickford et al., 2001). It is unlikely
therefore that chronic exposure to GDNFwould cause Purkinje cells
to becomeatrophic. Indeed, there is evidence to suggest that chronic
exposure to GDNF in CSF has protective effects on Purkinje cells in
vivo, as chronic ICV infusion of GDNF over 4 weeks rescues Purkinje
cells from hereditary degeneration in the shaker mutant rat model
(Tolbert et al., 2001). This is consistent with ﬁndings that GDNF
protects responsive neurons from excitotoxicity, possibly through
its ability to diminish free radical production (Gratacos et al., 2001;
Alberch et al., 2002; Cheng et al., 2004). Collectively, these data
support the conclusion that exposure of Purkinje cells to high
concentrations of GDNF over an extended time period would not
have been toxic but indeed would have been protective against
degenerative and excitotoxic mechanisms.
3.5. Withdrawal of GDNF in cerebrospinal ﬂuid
While the ﬁndings reviewed in Section 3.4 make it unlikely that
exposure to GDNF directly induces Purkinje cell loss, they raise the
related question of whether abrupt termination of exposure to
high concentrations of GDNF in CSF may have been the culprit
event.
If this were the case, it would be predicted that lesionswould be
observed exclusively in animals whose GDNF CCSF values were
below the limit of quantiﬁcation at necropsy, i.e., in animals that
were ‘‘withdrawn’’. This was indeed the case. Apart from the ﬁve
recovery animals in the high-dose group, there were two main
group animals that (like two of the recovery animals as well) had
GDNF CCSF values below the limit of quantiﬁcation at the end of
treatment (although the reasons for this are unknown and may
have been due to catheter migration or peripheral disconnection).
Three of the animals with Purkinje cell lesions belonged to the
recovery group, while the fourth one was one of the two main
group animals above. Hence, 4 of 7 high-dose animals with no
measurable levels of GDNF CCSF at necropsy had lesions, as
compared to 0 of 8 high-dose animals that were still exposed to
measurable concentrations. The probability that this split occurred
by chance is 0.026 (7  6  5  4/15  14  13  12), suggesting
that withdrawal played a causal role in the pathogenesis of the
lesions (Hutchinson, 2008).
Further insight can be gained by analyzing the individual
patterns of GDNF CCSF over time in the high-dose animals (Fig. 3).
The graph reveals that the four affected animals shared a
common pattern of GDNF CCSF over time that was otherwise seen in
only one unaffected animal in the recovery group (no. 35). In
particular, all of theseanimalshadGDNFCCSF values>1700 pg/mLat
Week 4 and/orWeek 26, and decreased to values below the limit of
quantiﬁcation at necropsy. Moreover, animals that presented with
high values only atWeek 4 (no. 28, 34, and 72) hadmild tominimal
lesionswith 1–3% of the cerebellar cortex affected, while animal no.
71 that presentedwith high values both atWeek 4 andWeek 26had
moderate lesions with 21% of the cerebellar cortex affected. Animal
no. 35 presented with a high value at Week 26 and remained
unaffected. All other animals (1) never exceeded the threshold of
1700 pg/mL (no. 68, 69, and 70), (2) had a more gradual decrease
between Week 4 andWeek 26 (no. 29), or (3) had values above the
threshold at necropsy (no. 32, 33, 64, 65, 66, and 67, as well as mid-
dose animals no. 19 and 56 (Hovland et al., 2007)).
In aggregate, these data suggest that the observed Purkinje cell
loss was caused by abrupt withdrawal following extended
exposure to GDNF CCSF values >1700 pg/mL. All of the affectedanimals shared the respective, characteristic pattern of GDNF CCSF
over time, and 4 of 5 animals that showed this pattern were
affected. Also, although the number of sampling time points was
limited, it seems that the length of exposure was correlated with
the severity of the lesions.
These data are consistent with the hypothesis that chronic
exposure to high GDNF CCSF in normal animals leads to suppression
of endogenous GDNF synthesis and receptor down-regulation on
Purkinje cells (Salvatore et al., 2006). While direct evidence for
GDNF-induced down regulation of GDNF receptors on cerebellar
Purkinje neurons is lacking, receptor down-regulation as an
important mechanism to attenuate growth factor-activated
receptor tyrosine kinase signaling is well established (Schlessinger,
2000). Ligand binding leads to receptor clustering in coated pits on
the cell surface, followed by endocytosis, intracellular trafﬁcking
and lysosomal degradation, processes that are in part regulated by
ligand-induced receptor ubiquitination (Schlessinger, 2000; Dikic
and Giordano, 2003; Thien and Langdon, 2005; Arevalo et al.,
2006). These mechanisms can abrogate receptor tyrosine kinase
signaling irreversibly (Alsina et al., 2012).
There is no reason to believe that this general principle does not
also apply to GDNF and its receptors. In fact, it is known that the
expression of GDNF receptors is not static and can undergo
dynamic changes. For example, GFRa-1 and GFRa-2 are progres-
sively down-regulated in postnatal spinal motoneurons (Zhang
and Huang, 2006), and exposure to toxins such as MPTP and
rotenone effects a robust down-regulation of c-RET in neurons
(Hirata and Kiuchi, 2007). Also, there are a number of studies
reporting that chronic long-term over-expression of GDNF has
adverse effects on both intact and Parkinsonian nigrostriatal
neurons (Georgievska et al., 2004a,b; Winkler et al., 2006). A
potential explanation for the latter ﬁndings is a direct negative
feedback mechanism involving GDNF receptors.
If receptor down-regulation is followed by abrupt withdrawal
of exogenously delivered GDNF, cells can become atrophic and
ultimately die via a caspase-dependent non-mitochondrial path-
way (Yu et al., 2003). The ﬁnding that Purkinje cells predominantly
express GDNF family ligand receptor GFRa-2 (Burazin and
Gundlach, 1999) further supports this hypothesis. As GDNF binds
to GFRa-2 at lower afﬁnities than to GFRa-1 (Airaksinen and
Saarma, 2002), higher GDNF concentrations and extended expo-
sure would be needed to induce receptor down-regulation, and
this would explain why lesions were observed exclusively in the
high-dose group.
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intermittent dosing ICV studies provides additional support for the
receptor down-regulation hypothesis. Animals in these studies
were exposed to very high peak GDNF CCSF values immediately
after dosing. As reported in Section 1.3, mean peak GDNF CCSF after
single dose ICV administration of 500 mg GDNF (1/6 of the highest
dose given in the ICV toxicology studies) was approximately
34 mg/mL (Lau, 1996), i.e. 3–6  103 higher than mean GDNF CCSF
at the high-dose level in the continuous dosing IPu study. However,
in the intermittent dosing ICV studies, exposure to high-GDNF CCSF
values of Purkinje cells was likely of insufﬁcient duration to induce
sustained down-regulation of the GFRa-2 receptor. As discussed
earlier, the elimination of GDNF from CSF following ICV
administration in rhesus monkeys ﬁts a tri-exponential model
with half-lives of 0.24, 6.6 and 34 h (Lau, 1996). This suggests that
exposure to GDNF in CSF ended within approximately one week
after dosing in the intermittent dosing ICV studies.
Therefore, cerebellar Purkinje cells were left unexposed for
3weeks before the next treatment took placewithmonthly dosing,
and still for one week before the next treatment took place with
biweekly dosing. Of note, CSF samples from the biweekly dosing
studywhichwere taken 2 days after the last dosing already yielded
GDNF CCSF values well below the hypothesized ‘‘critical threshold’’
of 1700 pg/mL in 2 of 4 animals both in the low-dose group
(600 mg/month) and the mid-dose group (2000 mg/month). Only
in the high-dose group (6000 mg/month) were the values
consistently above the threshold of 1700 pg/mL at 2 days after
the last dosing (Orr, 1996). No GDNF measurements in CSF are
available from the monthly dosing ICV study, since all CSF samples
were accidentally discarded before the analysis.
4. Clinical studies
Chronic, continuous delivery of GDNF into the putamen has
been investigated in 3 clinical studies to date, including two open-
label Phase I studies and a double-blind, placebo-controlled Phase
II study (Gill et al., 2003; Patel et al., 2005; Slevin et al., 2005; Lang
et al., 2006; Slevin et al., 2007). Overall, 49 subjects with PD
participated in these studies, 32 of whom were exposed to GDNF
over a period of up to 43 months. Doses ranged from 90 to
2592 mg/month, the most commonly used dose being 900 mg/
month. This translates to a safety margin of 14 (range: 4.9–140)
relative to the no-observed-adverse-effect-level (NOAEL) of
900 mg/month in the continuous dosing IPu toxicology study
(Hovland et al., 2007), when a standard scaling factor of 14 is
used to adjust for the differences between normal rhesus monkeys
and Parkinsonian humans in brain weight (95 g vs. 1350 g)
(Nieuwenhuys et al., 1998) or brain volume (97 cm3 [2_TD$DIFF] vs.
1470 cm3) (Yin et al., 2009b). Notably, the above approach to
the calculation of safety margins is valid only for toxicities in brain
regions that are remote to the putamenal site of delivery, e.g.
cerebellum. By contrast, safety margins for local parenchymal
toxicitieswould have to be calculated on the basis of Ci andwithout
considering spatial differences.
In none of the subjects were there any clinical signs or
symptoms of cerebellar atrophy. Upon identifying cerebellar
lesions in the continuous dosing IPu toxicology study in rhesus
monkeys, MRI scans from 9 of 10 subjects enrolled in one of the
Phase I studies were systematically analyzed to determine
whether subtle volumetric or intensity changes could be detected
in the cerebellum or elsewhere following GDNF treatment for over
1 year (Chebrolu et al., 2006). The analysis revealed no signiﬁcant
cerebellar differences in any of the subjects (difference image
analysis), no signiﬁcant morphometric differences between pre-
and post-GDNF scans (voxel-based group morphometric analysis),
and no signal abnormalities in the cerebellum on ﬂuid-attenuatedinversion-recovery (FLAIR) images (clinical scan review). One
subject who participated in the other Phase I study died from an
unrelated myocardial infarction 3 months after the cessation of
treatmentwith GDNF (Love et al., 2005). The drug had been infused
unilaterally at doses of 432–1296mg per month over a total of
43 months. Autopsy showed no evidence of cerebellar atrophy,
while there was a focal increase in astrocytic gliosis around the
catheter tract and limited inﬂammation at the catheter tip,
surrounded by a local increase in tyrosine hydroxylase-immuno-
positive nerve ﬁbers indicating signiﬁcant biological activity of
GDNF (Love et al., 2005).
5. Implications for clinical research
The clinical development program of GDNF in PD which was
halted in 2004 has recently been resumed employing a novel
intermittent dosing, convection-enhanced delivery (CED) para-
digm for local drug administration into the putamen (Bienemann
et al., 2011; Gill et al., 2012) [https://www.clinicaltrialsregister.eu/
ctr-search/trial/2011-003866-34/GB]. CED is a technique that has
been introduced to overcome the limitations of diffusion-based
delivery (Bobo et al., 1994). It is enabled by a continuous local
pressure gradient that is generated by a pressurized infusion
system and forces the infusate from the site of deposition through
the extracellular space (Bobo et al., 1994; Allard et al., 2009). The
resulting bulk ﬂow leads to reproducible, homogeneous drug
distribution throughout clinically signiﬁcant volumes of brain
parenchyma (Bobo et al., 1994; Morrison et al., 1994; Lieberman
et al., 1995). Unlike diffusion, CED is not signiﬁcantly inﬂuenced by
the concentration and molecular weight or particle size of the
infused agent (Bobo et al., 1994; Lieberman et al., 1995; Croteau
et al., 2005; Allard et al., 2009).
All previous clinical studies testing IPu administration of GDNF
employed continuous infusion schemes at ﬂow rates of 0.1 mL/min
or less (Gill et al., 2003; Patel et al., 2005; Slevin et al., 2005; Lang
et al., 2006; Slevin et al., 2007), supplemented with short 2-min
pulses at 10.9mL/min every 6 h in one of the Phase I studies (Slevin
et al., 2005; Slevin et al., 2007). It has since been established that
ﬂow rates of 0.5 mL/min or more are needed to induce effective
convection (Fiandaca et al., 2008; Allard et al., 2009). Application of
the low-ﬂow Phase II delivery protocol in rhesus monkeys
produced minimal putamenal coverage and highly variable and
irregular distribution of GDNF (Salvatore et al., 2006). It should be
borne in mind that utilization of CED-enabling ﬂow rates
continuously over extended times would inevitably lead to drug
distributions beyond the desired target volume (‘‘ﬂooding’’) and
leakage into white matter and/or the CSF compartment. As leakage
into the CSF is likely the ﬁrst step in the chain of events that
eventually leads to cerebellar lesions (Varenika et al., 2008;
Fiandaca et al., 2008), this must be avoided. Therefore, this
hypothesis would dictate that chronic CED can only be utilized
safely (from a cerebellar toxicity perspective) with intermittent
dosing regimens.
In addition to the generic technical requirement for the
intermittent use of CED, there is a biological case for intermittent
delivery of GDNF. Notably, the activity of GDNF, both upstream as
assessed by dopamine turnover and downstream as assessed by
local synaptophysin concentrations, has been shown to remain
elevated over several weeks after single dose administration via
CED into the striatum of normal rats (Hadaczek et al., 2010; Taylor
et al., 2013). This is consistent with earlier behavioral data in
Parkinsonian nonhuman primates showing sustained functional
improvements over 4 weeks following single intranigral, intra-
caudate or ICV administration (Gash et al., 1996). Finally, and
perhaps most importantly, intermittent delivery would be
projected to reduce the possibility of generating ligand-induced
M. Luz et al. / NeuroToxicology 52 (2016) 46–56 55receptor down-regulation both on target and non-target neurons.
At the same time, intermittent delivery is associated with the use
of markedly lower total doses (temporally normalized), thus
increasing the safety margins relative to the cerebellar toxicity-
based NOAEL of 900mg per month determined in the continuous
dosing IPu toxicology study (Hovland et al., 2007).
In conclusion, review of the available evidence suggests that
further clinical testing of intraputamenally administeredGDNF can
be safely pursued in PD subjects as long as the molecule is
delivered intermittently and via CED.
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